89 related articles for article (PubMed ID: 8307160)
1. Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts.
Rabbani SA; Rajwans N; Achbarou A; Murthy KK; Goltzman D
FEBS Lett; 1994 Jan; 338(1):69-74. PubMed ID: 8307160
[TBL] [Abstract][Full Text] [Related]
2. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
3. Differential binding of urokinase and peptide antagonists to the urokinase receptor: evidence from characterization of the receptor in four primate species.
Engelholm LH; Behrendt N
Biol Chem; 2001 Mar; 382(3):435-42. PubMed ID: 11347891
[TBL] [Abstract][Full Text] [Related]
4. The structure of the urokinase-type plasminogen activator receptor gene.
Casey JR; Petranka JG; Kottra J; Fleenor DE; Rosse WF
Blood; 1994 Aug; 84(4):1151-6. PubMed ID: 8049431
[TBL] [Abstract][Full Text] [Related]
5. An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator.
Pyke C; Eriksen J; Solberg H; Nielsen BS; Kristensen P; Lund LR; Danø K
FEBS Lett; 1993 Jul; 326(1-3):69-74. PubMed ID: 8392005
[TBL] [Abstract][Full Text] [Related]
6. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
[TBL] [Abstract][Full Text] [Related]
7. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator system in osteoclasts.
Yang JN; Allan EH; Anderson GI; Martin TJ; Minkin C
J Bone Miner Res; 1997 May; 12(5):761-8. PubMed ID: 9144342
[TBL] [Abstract][Full Text] [Related]
9. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.
Bugge TH; Flick MJ; Danton MJ; Daugherty CC; Romer J; Dano K; Carmeliet P; Collen D; Degen JL
Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5899-904. PubMed ID: 8650190
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor.
Montuori N; Salzano S; Rossi G; Ragno P
FEBS Lett; 2000 Jul; 476(3):166-70. PubMed ID: 10913606
[TBL] [Abstract][Full Text] [Related]
12. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract.
Kristensen P; Eriksen J; Blasi F; Danø K
J Cell Biol; 1991 Dec; 115(6):1763-71. PubMed ID: 1661735
[TBL] [Abstract][Full Text] [Related]
13. Increased invasion of neuroglioma cells transfected with urokinase plasminogen activator receptor cDNA.
Mohanam S; Chintala SK; Mohan PM; Sawaya R; Lagos GK; Gokaslan ZL; Kouraklis GP; Rao JS
Int J Oncol; 1998 Dec; 13(6):1285-90. PubMed ID: 9824646
[TBL] [Abstract][Full Text] [Related]
14. Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR.
Fowler B; Mackman N; Parmer RJ; Miles LA
Thromb Haemost; 1998 Jul; 80(1):148-54. PubMed ID: 9684801
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
Montuori N; Mattiello A; Mancini A; Taglialatela P; Caputi M; Rossi G; Ragno P
Int J Cancer; 2003 Jun; 105(3):353-60. PubMed ID: 12704669
[TBL] [Abstract][Full Text] [Related]
16. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
17. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
Türkmen B; Schmitt M; Schmalfeldt B; Trommler P; Hell W; Creutzburg S; Graeff H; Magdolen V
Electrophoresis; 1997 May; 18(5):686-9. PubMed ID: 9194591
[TBL] [Abstract][Full Text] [Related]
19. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
20. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells.
Busso N; Masur SK; Lazega D; Waxman S; Ossowski L
J Cell Biol; 1994 Jul; 126(1):259-70. PubMed ID: 7517943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
